Parkinson’s disease may leave a molecular trail in the bloodstream long before its most disabling symptoms become impossible to miss. A study published in npj Parkinson’s Disease reports that patterns of gene activity in peripheral blood are associated with two clinically important features of the disorder: cognitive impairment and freezing of gait. The work, by R. Lee and M. Park, uses a data-driven transcriptomic approach to examine whether circulating blood cells carry a measurable signature linked to the way Parkinson’s disease affects thinking and movement. The findings do not suggest that a blood test can yet diagnose these complications on its own, but they strengthen a rapidly developing idea in neurology: that the immune and molecular signals found outside the brain may provide a window into disease processes that are otherwise difficult to observe in living patients.
Parkinson’s disease is best known for tremor, slowness of movement, rigidity and problems with balance, yet its clinical landscape is far broader. Cognitive impairment can affect attention, executive function, memory and the ability to manage complex tasks. Freezing of gait, meanwhile, is a sudden and often frightening inability to initiate or continue walking, commonly experienced as if the feet have become glued to the floor. It can occur when a person turns, approaches a doorway, encounters an obstacle or faces a change in surface. Both complications are associated with loss of independence and increased fall risk, but they do not appear in exactly the same way or at the same pace in every patient. That variability has made it difficult for clinicians to predict who is most vulnerable using symptoms and routine examinations alone.
The new research focuses on the transcriptome, the collection of RNA molecules produced by genes in a particular biological sample at a particular moment. Unlike the genome, which is largely fixed, the transcriptome changes in response to disease, inflammation, medication, metabolism and environmental influences. Researchers can measure thousands of RNA transcripts simultaneously, generating a molecular profile of which genes are more active or less active in blood cells. In a data-driven analysis, computational methods are then used to identify combinations of transcripts that distinguish clinical groups or correlate with specific features of disease. These combinations are often called signatures. They are not necessarily single disease-causing genes; instead, they can reflect coordinated biological programs, such as immune activation, cellular stress, altered energy production or changes in communication between tissues.
The appeal of peripheral blood is practical as well as scientific. Brain tissue is inaccessible in living patients, and advanced imaging or spinal-fluid sampling can be expensive, invasive or difficult to repeat. Blood can be collected routinely, making it a potentially scalable source for biomarkers that could support earlier risk assessment and more individualized care. The study’s central observation is that peripheral blood transcriptomic patterns are associated with cognitive impairment and freezing of gait in people with Parkinson’s disease. This association suggests that the blood-based molecular profile may capture biological differences between patients whose disease remains primarily motor and those who develop more complex neurological complications. It also raises the possibility that systemic immune signaling, vascular biology or other body-wide processes may interact with brain circuits involved in cognition and locomotion.
The connection between blood and the Parkinson’s brain is biologically plausible, although it is not simple. Blood cells constantly respond to signals released by organs and tissues, while inflammatory molecules and metabolic factors can influence the integrity of the blood–brain barrier and the function of neural networks. Parkinson’s disease itself involves the misfolding and accumulation of alpha-synuclein, degeneration of dopamine-producing neurons and disruption of several interconnected brain systems. Cognitive impairment and gait freezing are thought to involve more than dopamine loss alone. They can reflect dysfunction across frontal, basal ganglia, brainstem and attentional networks, as well as changes in neurotransmitters including acetylcholine and noradrenaline. A blood transcriptomic signature could therefore be valuable not because it directly measures one lesion in the brain, but because it may record the wider biological state accompanying these complex network failures.
The data-driven nature of the analysis is particularly important. Rather than selecting a small number of genes in advance, computational screening can search broadly across the transcriptome for patterns associated with clinical outcomes. Statistical and machine-learning techniques may then reduce thousands of measurements to a smaller set of informative features. Such methods can reveal relationships that would be difficult to detect through conventional hypothesis testing, but they also create a major risk: a model may learn the quirks of one dataset instead of the biology of Parkinson’s disease. The strongest signatures must therefore be tested in independent patient groups, assessed for reproducibility and evaluated against factors such as age, sex, medication, disease duration, sleep, depression, physical activity and other medical conditions. The reported association is an important research signal, but it is not proof that the identified transcripts cause cognitive impairment or freezing of gait.
That distinction matters for patients and families. A molecular signature can be correlated with a clinical feature without being capable of predicting it in an individual person. Before a blood-based test could enter routine care, researchers would need to establish its sensitivity, specificity and clinical usefulness. They would also need to determine whether the signature remains stable over time, changes as symptoms progress or responds to treatment. A useful biomarker should ideally provide information beyond a neurologist’s examination and standard cognitive or gait assessments. It might help identify patients who need closer monitoring, guide the selection of participants for clinical trials or reveal biological subgroups that respond differently to therapies. But those possibilities require prospective validation, transparent reporting and careful comparison with existing clinical measures.
The study also points toward a broader shift in Parkinson’s research, from treating the disease as a single condition to understanding it as a collection of interacting biological subtypes. Two people may receive the same diagnosis while having very different trajectories: one may experience years of predominantly motor symptoms, while another develops cognitive changes, balance problems or gait freezing relatively early. Transcriptomics could help map these trajectories by identifying molecular programs that accompany distinct patterns of progression. Combined with imaging, digital walking measurements, genetic information and detailed neurological assessments, blood RNA profiles might eventually contribute to precision medicine. The most powerful future tools may not be single biomarkers, but integrated models that connect molecular signals to real-world function, such as how often a patient freezes while walking at home or how rapidly attention declines.
For now, the work by Lee and Park offers a provocative glimpse of how a routine blood sample might help illuminate some of Parkinson’s disease’s hardest-to-predict complications. Its significance lies less in promising an immediate diagnostic breakthrough than in demonstrating the potential of peripheral molecular data to reflect clinically meaningful differences within the disorder. Cognitive impairment and freezing of gait remain major challenges because they arise from distributed and evolving neural dysfunction, not from one easily measured defect. If the reported transcriptomic signature survives testing in larger and more diverse populations, it could become part of a new generation of biomarkers designed to anticipate those challenges earlier and monitor them more precisely. The blood may not tell the whole story of Parkinson’s disease, but it could prove to be one of the most accessible chapters.
Subject of Research: Peripheral blood transcriptomic signatures associated with cognitive impairment and freezing of gait in Parkinson’s disease.
Article Title: Peripheral blood transcriptomic signature is associated with cognitive impairment and freezing of gait in Parkinson’s disease: a data-driven approach.
Article References: Lee, R., Park, M. “Peripheral blood transcriptomic signature is associated with cognitive impairment and freezing of gait in Parkinson’s disease: a data-driven approach.” npj Parkinson’s Disease (2026). https://doi.org/10.1038/s41531-026-01527-0
Image Credits: AI Generated
DOI: 10.1038/s41531-026-01527-0
Keywords: Parkinson’s disease, peripheral blood, transcriptomics, cognitive impairment, freezing of gait, biomarkers, precision medicine, RNA profiling, neurology, machine learning
Tags: blood-based biomarkers for freezing gaitblood-based diagnostics for neurological disorderscirculating blood gene activity in Parkinson’searly detection of Parkinson’s disease symptomsgenetic patterns linked to Parkinson’s motor symptomsimmune signals in Parkinson’s diseasemolecular biomarkers for Parkinson’s cognitive impairmentmolecular markers for Parkinson’s cognitive declinenon-invasive blood tests for Parkinson’sParkinson’s disease blood gene signatureperipheral blood gene signatures and neurodegenerationtranscriptomic analysis in Parkinson’s
